why choose us

First received: May 26, 2023

Clinical Trial: First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

Study Status: Completed

Recruit Status: RECRUITING

Condition: EGFR Mutant Advanced Non-Small Cell Lung Cancer

Study Type: INTERVENTIONAL


Official Title: First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

Brief Summary: This is an open label, multi-center, Phase 1/2 study evaluating the safety, tolerability, PK, PD, and preliminary efficacy (antitumor activity) of BBT-207.It will consist of 3 parts; dose escalation, recommended phase 2 dose selection, and dose expansion.

Read more